RNA Company Profile and Key Details

Atrium Therapeutics, Inc. (NASDAQ:RNA) closed at $12.34 USD, gaining $0.23 (1.90%) from the previous close of $12.11. The stock is currently mid-range between its 52-week high and low $11.13 and $16.77. With a market capitalization of about $211.08 million, Atrium Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 196.02 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Atrium Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kathleen Gallagher, the company employs approximately 511 people and listed since February 27, 2026. Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart.

Short-term trend indicators are bearishly aligned (SMA20 0.0%, SMA50 0.42%, SMA200 38.79%). The stock’s 14-day RSI is 57.58 (neutral), while the ATR of 0.22 points to moderate volatility. The stock remains hovering near 52-week lows, trading -0.36% below its high and over 238.45% above its low. Average 10-day trading volume of 129.27 thousand shares is below the 3-month average of 194.44 thousand, indicating normal recent market interest.

Atrium Therapeutics, Inc. trades at a P/E ratio of -4.62, slightly below the S&P 500 average, with a price-to-sales ratio of 10.3 and a price-to-book ratio of 0.9 suggesting the stock is closer to book value. The P/FCF stands at -3.95, also above market averages.

Atrium Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.33. This means the shares are trading below this model’s fair value.

Atrium Therapeutics, Inc. generated EPS of -$4.96 over the past year. Five-year average earnings growth is -19.41%. Wall Street analysts project EPS growth of -11.51% annually over the next five years. The latest quarter delivered EPS of -$0.97. The next quarter is forecast at -$1.32. Next year's EPS is expected at -$28.91. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 6 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $87.00 to $25.00. The high target offers 605.02% upside. The low target suggests 102.59% downside. The mean target is $61.16. This offers 395.62% upside. Atrium Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -7.62%. The prior quarter beat by 37.1%. Over the last six quarters, Apple has recorded several small beats. These include 2.27% in May 08, 2025.

Atrium Therapeutics, Inc. has 128.65 million shares outstanding. The public float is 98.07 million shares, elevated short interest at 12.71% of float. This equals 16.21 million shares. The short ratio is 6.27 days. Institutional investors hold 93.22% of the float. Insiders own 4.27%. RTW INVESTMENTS, LP holds 4.80 million shares, Cormorant Asset Management, LP has 2.51 million shares and Boyce Sarah has 269.01 thousand shares.